Rifagut200 mg

Rifagut 200 mg is indicaed in- Treatment of traveler's diarrhea by noninvasive strains of E. coli reduction in risk of overt hepatic encephalopathy bacterial overgrowth of irritable bowel syndrome.

4-Quinolone preparations

Rifagut 200 mg is a non-systemic, rifamycin antibiotic which is structural analog of rifampin. Rifagut 200 mg acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis.

For traveler's diarrhea (>12 years of age): The recommended dose of Rifagut 200 mg is 200 mg taken orally three times a day for 3 days. For hepatic encephalopathy (>18 years of age): The recommended dose of Rifagut 200 mg is 550 mg taken orally two times a day.Rifagut 200 mg can be administered orally, with or without food.

Traveler's Diarrhea: For patients ≥12 years of age: 200 mg 3 times daily for 3 days.Hepatic Encephalopathy: For patients ≥18 years of age: 550 mg 2 times daily.Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food

In an in vitro study has suggested that Rifagut 200 mg induces CYP3A4. However, in patients with normal liver function, Rifagut 200 mg at the recommended dosing regimen is not expected to induce CYP3A4.

Contraindicated in patients with a hypersensitivity to Rifagut 200 mg or to any of the rifamycin antimicrobial agents, or any components of this product

Side effects include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, constipation, pyrexia, vomiting. Reactions have been reported, including anaphylaxis, angioneurotic edema, and exfoliative dermatitis.

Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Based on animal data, Rifagut 200 mg may cause fetal harm. It should be used during pregnancy only if the potential benefit outweighs the probable risk to the fetus. Discontinue nursing or drug, taking into account the importance of the drug to the mother.

Rifagut 200 mg is not found to be effective in patients with diarrhea complicated by fever and/or blood in the stools. Rifagut 200 mg therapy should be discontinued if diarrhea symptoms get worse or persist for more than 24-48 hours and alternative antibiotic therapy should be considered. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

No specific information is available on the treatment of over dosage with Rifagut 200 mg. In case of over dosage, discontinue Rifagut 200 mg, treat symptomatically and institute supportive measures as required.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

4-Quinolone preparations

Rifagut 200 mg is a semisynthetic, rifamycin-based non-systemic antibiotic. Very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. Rifagut 200 mg inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. It shows the same broad spectrum activity as rifamycin which exerts bactericidal action against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.

Pregnancy category C. It is not known whether Rifagut 200 mg is excreted in human milk or not.

Renal Impairment: The pharmacokinetics of Rifagut 200 mg in patients with impaired renal function has not been studied.Hepatic Impairment: The systemic exposure of Rifagut 200 mg was markedly elevated in patients with hepatic impairment compared to healthy subjects.